Cadonilimab plus regorafenib for advanced colorectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (cadonilimab plus regorafenib) as a possible third-line option for people with colorectal cancer that has spread to the liver. It is for patients whose cancer is the MSS/pMMR type and who have already tried standard treatments without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colon or rectal cancer that has spread to your liver (may also have spread elsewhere).
- You have tried at least one standard treatment (like FOLFOX, FOLFIRI, bevacizumab, or cetuximab/panitumumab) and it stopped working or you couldn't tolerate it.
- Your tumor is the MSS (microsatellite stable) or pMMR type.
- You have not already received any third-line treatments such as regorafenib, fruquintinib, trifluridine tipiracil, or immunotherapy drugs.
- Your liver, kidney, and blood counts are within a certain healthy range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
This trial tests a combination of two drugs (regorafenib and sintilimab) plus electroacupuncture for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to see if this triple therapy can help shrink tumors or slow the cancer's growth.
This Phase 2 study tests whether taking regorafenib alone or with immunotherapy (toripalimab) and a lower-dose radiation plan can better control metastatic colon or rectal cancer that has MSS/pMMR. It may help by combining cancer-blocking medicine with immune activation and focused radiation to metastatic spots.
This trial tests a combination of four drugs for people with advanced colorectal cancer who have already tried at least two other treatments. The goal is to see if this new mix can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
Hear when a new CRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.